Clinica Baviera (CBAV) Q4 2025 earnings summary

Executive summary

• Revenue increased by up to 15% year-over-year, with net profit up as much as 15% and growth in all operating countries.

• Eleven new clinics opened, strengthening market position and expanding the patient base.

• Strategic priorities include investment in technology, international expansion, operational excellence, and brand strengthening, with a focus on optimizing UK operations and improving profitability in Italy.

• Share price appreciated by 59% during the year.

• No significant subsequent events occurred after year-end closing.

Financial highlights

• Consolidated revenue reached €301.8 million, up from €270.0 million (+12% to +15%).

• EBITDA grew up to 12% to €84.5 million; net profit rose up to 15% to €42.9 million.

• Earnings per share increased to €2.58 (+12%).

• Net financial position improved to €42.4 million (+39%).

• Dividend per share stable at €1.57.

Outlook and guidance

• Optimism for 2026, the 35th anniversary, driven by operational improvements, AI adoption, and continued digital transformation.

• Continued focus on growth in existing cities, selective new openings, and international expansion, especially in the UK and Italy.

• Strategic emphasis on operational efficiency, technological leadership, and brand consolidation.

• Demographic trends and diversification of treatments expected to support medium-term growth.